Literature DB >> 28104736

Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder.

Erik Joas1, Alina Karanti1, Jie Song1, Guy M Goodwin1, Paul Lichtenstein1, Mikael Landén2.   

Abstract

BackgroundClinical trials have examined the efficacy of drugs to prevent relapse in patients with bipolar disorder, however, their design often limits generalisation to routine clinical practice.AimsTo estimate the effectiveness of drugs used for maintenance treatment in bipolar disorder.MethodWe used national registers to identify 35 022 individuals diagnosed with bipolar disorder and information on lithium, valproate, carbamazepine, lamotrigine, quetiapine and olanzapine treatment from 2006 to 2009. The main outcome was psychiatric hospital admissions. We used stratified cox regression to compare periods on and off medication within the same individual.ResultsMedication with lithium, valproate, lamotrigine, olanzapine and quetiapine was associated with reduced rates of admission to hospital. Lithium was more effective than quetiapine and olanzapine. The effects of specific drugs depended on the polarity of the mood episode.ConclusionsOur findings complement results from randomised controlled trails, but suggest that lithium is more effective than both quetiapine and olanzapine in routine clinical practice. © The Royal College of Psychiatrists 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28104736     DOI: 10.1192/bjp.bp.116.187989

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

1.  Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder.

Authors:  Markku Lähteenvuo; Antti Tanskanen; Heidi Taipale; Fabian Hoti; Pia Vattulainen; Eduard Vieta; Jari Tiihonen
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

2.  Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders.

Authors:  Anastasiya Nestsiarovich; Aurélien J Mazurie; Nathaniel G Hurwitz; Berit Kerner; Stuart J Nelson; Annette S Crisanti; Mauricio Tohen; Ronald L Krall; Douglas J Perkins; Christophe G Lambert
Journal:  Bipolar Disord       Date:  2018-06-19       Impact factor: 6.744

3.  Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study.

Authors:  Michael Ott; Björn Forssén; Ursula Werneke
Journal:  Ther Adv Psychopharmacol       Date:  2019-04-04

4.  Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report.

Authors:  Anna Maria Szota; Izabela Radajewska; Przemysław Grudzka; Aleksander Araszkiewicz
Journal:  BMC Psychiatry       Date:  2020-04-19       Impact factor: 3.630

5.  Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study.

Authors:  Louise Öhlund; Michael Ott; Sofia Oja; Malin Bergqvist; Robert Lundqvist; Mikael Sandlund; Ellinor Salander Renberg; Ursula Werneke
Journal:  BMC Psychiatry       Date:  2018-02-07       Impact factor: 3.630

6.  Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: An ISBD task force report.

Authors:  Kenneth I Shulman; Osvaldo P Almeida; Nathan Herrmann; Ayal Schaffer; Sergio A Strejilevich; Christina Paternoster; Sean Amodeo; Annemiek Dols; Martha Sajatovic
Journal:  Bipolar Disord       Date:  2018-11-16       Impact factor: 6.744

7.  Psychoeducation for bipolar disorder and risk of recurrence and hospitalization - a within-individual analysis using registry data.

Authors:  Erik Joas; Kristoffer Bäckman; Alina Karanti; Timea Sparding; Francesc Colom; Erik Pålsson; Mikael Landén
Journal:  Psychol Med       Date:  2019-05-06       Impact factor: 7.723

8.  Lithium-associated hypothyroidism and potential for reversibility after lithium discontinuation: Findings from the LiSIE retrospective cohort study.

Authors:  Ingrid Lieber; Michael Ott; Louise Öhlund; Robert Lundqvist; Mats Eliasson; Mikael Sandlund; Ursula Werneke
Journal:  J Psychopharmacol       Date:  2019-10-31       Impact factor: 4.153

9.  Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: mirror-image study based on the LiSIE retrospective cohort.

Authors:  Louise Öhlund; Michael Ott; Malin Bergqvist; Sofia Oja; Robert Lundqvist; Mikael Sandlund; Ellinor Salander Renberg; Ursula Werneke
Journal:  BJPsych Open       Date:  2019-11-22

10.  Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Liping Hou; Scott R Clark; Sergi Papiol; Micah Cearns; Urs Heilbronner; Franziska Degenhardt; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Tatyana Shekhtman; Mazda Adli; Nirmala Akula; Kazufumi Akiyama; Raffaella Ardau; Bárbara Arias; Jean-Michel Aubry; Lena Backlund; Abesh Kumar Bhattacharjee; Frank Bellivier; Antonio Benabarre; Susanne Bengesser; Joanna M Biernacka; Armin Birner; Clara Brichant-Petitjean; Pablo Cervantes; Hsi-Chung Chen; Caterina Chillotti; Sven Cichon; Cristiana Cruceanu; Piotr M Czerski; Nina Dalkner; Alexandre Dayer; Maria Del Zompo; J Raymond DePaulo; Bruno Étain; Stephane Jamain; Peter Falkai; Andreas J Forstner; Louise Frisen; Mark A Frye; Janice M Fullerton; Sébastien Gard; Julie S Garnham; Fernando S Goes; Maria Grigoroiu-Serbanescu; Paul Grof; Ryota Hashimoto; Joanna Hauser; Stefan Herms; Per Hoffmann; Andrea Hofmann; Esther Jiménez; Jean-Pierre Kahn; Layla Kassem; Po-Hsiu Kuo; Tadafumi Kato; John R Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Barbara König; Ichiro Kusumi; Gonzalo Laje; Mikael Landén; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Alfonso Tortorella; Mirko Manchia; Lina Martinsson; Michael J McCarthy; Susan L McElroy; Francesc Colom; Marina Mitjans; Francis M Mondimore; Palmiero Monteleone; Caroline M Nievergelt; Markus M Nöthen; Tomas Novák; Claire O'Donovan; Norio Ozaki; Urban Ösby; Andrea Pfennig; James B Potash; Andreas Reif; Eva Reininghaus; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Barbara W Schweizer; Giovanni Severino; Paul D Shilling; Katzutaka Shimoda; Christian Simhandl; Claire M Slaney; Alessio Squassina; Thomas Stamm; Pavla Stopkova; Mario Maj; Gustavo Turecki; Eduard Vieta; Julia Veeh; Stephanie H Witt; Adam Wright; Peter P Zandi; Philip B Mitchell; Michael Bauer; Martin Alda; Marcella Rietschel; Francis J McMahon; Thomas G Schulze; Bernhard T Baune
Journal:  Mol Psychiatry       Date:  2020-03-16       Impact factor: 13.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.